Project Summary
Itch is a complex physiological process that incorporates detection of irritants by sensory neurons in the skin
which activate spinal interneurons and ultimately, cortical projection neurons to generate a response. G
protein-coupled receptors (GPCRs) play an integral role at each level of itch sensation and transmission.
Although conventionally considered cell surface receptors that are desensitized and internalized following
ligand binding, new evidence has established the ability of GPCRs to signal from endosomes. However, little
is known about the mechanisms that regulate endosomal signaling of GPCRs and nothing is known about
the role of endosomal GPCRs signaling in itch or whether endosomal GPCRs are a viable therapeutic target
for itch. This proposal hypothesizes that: 1. Gastrin releasing peptide receptor (GRPR) and neurokinin 1
receptor (NK1R), two key receptors in itch transmission in the spinal cord, can recruit and assemble multi-
protein complexes from the endosomal compartment that facilitate endosomal signaling and mediate
prolonged hyperexcitability of spinal interneurons. That the ability of GRPR and NK1R to signaling from
endosomes leads to itch transmission in the spinal cord and endocytic inhibitors that block GRPR and NK1R
endosomal signaling can inhibit scratching behavior in mice. 2. Targeting endosomal signaling of GRPR and
NK1R using nanoparticles is a more effective strategy in inhibiting itch than targeting cell surface receptors.
Endosomal signaling of GRPR and NK1R will be characterized in model cell lines, spinal interneurons that
mediate itch transmission, and in intact animals. Pharmaceutical and genetic approaches will be used to
inhibit endosomal trafficking of GRPR and NK1R. Aim 1 will characterize the importance of endosomal
trafficking and signaling of GRPR and NK1R in spinal interneurons for the transmission of itch. The role of
endosomal signaling in itch will be addressed by electrophysiology, and by itch behavioral assays in intact
animals. Aim 2 will characterize the ability of GRPR to traffic to endosomes and assemble the multi-protein
complexes that result in subcellular specific signaling events. These signaling complexes will be studied using
advanced biophysical and imaging approaches with high spatiotemporal resolution. Aim 3 will use advanced
chemical biology, nanoengineering and nanoparticle encapsulation to deliver GRPR and NK1R antagonists
to endosomes, probing the importance of endosomal signaling of GRPR and NK1R in itch transmission and
to determine whether endosomal GPCRs are a viable therapeutic target.